Mycobacterium tuberculosis dihydrofolate reductase inhibitors: State of Art Past 20 Years (2023)
Source: Biointerface Research in Applied Chemistry. Unidades: ICB, FCF
Subjects: TUBERCULOSE, FÁRMACOS, MYCOBACTERIUM TUBERCULOSIS, MICROBIOLOGIA, ANTIBIÓTICOS, INIBIDORES DE ENZIMAS
ABNT
VASSILIADES, Sandra Valeria et al. Mycobacterium tuberculosis dihydrofolate reductase inhibitors: State of Art Past 20 Years. Biointerface Research in Applied Chemistry, v. 13, n. 1 p. 1-20 art. 79, 2023Tradução . . Disponível em: https://doi.org/10.33263/BRIAC131.079. Acesso em: 26 ago. 2024.APA
Vassiliades, S. V., Navarausckas, V. B., Dias, M. V. B., & Parise Filho, R. (2023). Mycobacterium tuberculosis dihydrofolate reductase inhibitors: State of Art Past 20 Years. Biointerface Research in Applied Chemistry, 13( 1 p. 1-20 art. 79). doi:10.33263/BRIAC131.079NLM
Vassiliades SV, Navarausckas VB, Dias MVB, Parise Filho R. Mycobacterium tuberculosis dihydrofolate reductase inhibitors: State of Art Past 20 Years [Internet]. Biointerface Research in Applied Chemistry. 2023 ; 13( 1 p. 1-20 art. 79):[citado 2024 ago. 26 ] Available from: https://doi.org/10.33263/BRIAC131.079Vancouver
Vassiliades SV, Navarausckas VB, Dias MVB, Parise Filho R. Mycobacterium tuberculosis dihydrofolate reductase inhibitors: State of Art Past 20 Years [Internet]. Biointerface Research in Applied Chemistry. 2023 ; 13( 1 p. 1-20 art. 79):[citado 2024 ago. 26 ] Available from: https://doi.org/10.33263/BRIAC131.079